Analysts think NBIX stock price could increase by 29%
Aug 05, 2025, 11:25 AM
6.21%
What does NBIX do
Neurocrine Biosciences, based in San Diego, develops pharmaceuticals for neurological disorders and employs 1,448 people. Its FDA-approved products include INGREZZA and Orilissa, with a strong clinical development pipeline.
28 analysts think NBIX stock price will increase by 29.31%. The current median analyst target is $165.75 compared to a current stock price of $128.18. The lowest analysts target is $116.15 and the highest analyst target is $201.60.
📡️ Health Care
Price Target
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
